CG Oncology Inc CGON
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $69.50
- Day Range
- $68.72–72.92
- 52-Week Range
- $23.65–77.00
- Bid/Ask
- $62.00 / $76.50
- Shares Outstanding
- 88.20M
- Market Cap
- $6.34B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,124.80
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 142
- Website
- https://www.cgoncology.com
Valuation
|
Metric
|
CGON
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.79 |
Price/Sales | 1,124.80 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CGON
|
|---|---|
Quick Ratio | 30.60 |
Current Ratio | 31.30 |
Interest Coverage | — |
Quick Ratio
CGON
Profitability
|
Metric
|
CGON
|
|---|---|
Return on Assets (Normalized) | −19.31% |
Return on Equity (Normalized) | −20.20% |
Return on Invested Capital (Normalized) | −23.69% |
Return on Assets
CGON
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>V$V>xn | LOCK|c^ND& | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>x#!Tcr | LOCK|Ts@Z | $71B | |||
| argenx SE ADR
ARGX
| LOCK|bLPXRD | LOCK|BdH | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|L&wf&v | LOCK|TD | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Nlx!$$ | LOCK|tXl$Q | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|z&&<!^c | LOCK|?#kG | $26B | |||
| Moderna Inc
MRNA
| LOCK|>@Lq$$ | LOCK|&G# | $25B | |||
| Incyte Corp
INCY
| LOCK|rGvpf@h | LOCK|>p | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^@@N<dg | LOCK|tr | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Nl!bL&# | LOCK|Z^l | $16B |
United States